September 27, 2014
Crizotinibe em Câncer de Pulmão Não Pequenas Células com Rearranjo de ROS1
Key Points
Key points are not available for this paper at this time.
Abstract
Neste estudo, o crizotinibe mostrou marcante atividade antitumoral em pacientes com NSCLC avançado com rearranjo de ROS1. O rearranjo de ROS1 define um segundo subgrupo molecular de NSCLC para o qual o crizotinibe é altamente ativo. (Financiado pela Pfizer e outros; número ClinicalTrials.gov, NCT00585195.)
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...
Authors
Alice T. Shaw
Université Paris-Sud
S
Sai‐Hong Ignatius Ou
University of California, Irvine
Yung‐Jue Bang
Rutgers, The State University of New Jersey
Journals
New England Journal of Medicine
Actions
Institutions
University of Chicago
Massachusetts General Hospital
Dana-Farber Cancer Institute
References and Citations
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...